Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.74
CDXC's Cash-to-Debt is ranked lower than
68% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CDXC: 2.74 )
Ranked among companies with meaningful Cash-to-Debt only.
CDXC' s Cash-to-Debt Range Over the Past 10 Years
Min: 1  Med: 4.07 Max: No Debt
Current: 2.74
Equity-to-Asset 0.51
CDXC's Equity-to-Asset is ranked lower than
70% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CDXC: 0.51 )
Ranked among companies with meaningful Equity-to-Asset only.
CDXC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.43 Max: 0.76
Current: 0.51
0.28
0.76
Piotroski F-Score: 4
Altman Z-Score: 4.40
Beneish M-Score: -0.81
WACC vs ROIC
9.61%
-26.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -8.38
CDXC's Operating Margin % is ranked higher than
67% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CDXC: -8.38 )
Ranked among companies with meaningful Operating Margin % only.
CDXC' s Operating Margin % Range Over the Past 10 Years
Min: -100.22  Med: -34.16 Max: -8.37
Current: -8.38
-100.22
-8.37
Net Margin % -10.92
CDXC's Net Margin % is ranked higher than
66% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CDXC: -10.92 )
Ranked among companies with meaningful Net Margin % only.
CDXC' s Net Margin % Range Over the Past 10 Years
Min: -100.45  Med: -35.19 Max: -10.92
Current: -10.92
-100.45
-10.92
ROE % -31.84
CDXC's ROE % is ranked higher than
52% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CDXC: -31.84 )
Ranked among companies with meaningful ROE % only.
CDXC' s ROE % Range Over the Past 10 Years
Min: -3800  Med: -101.53 Max: -31.84
Current: -31.84
-3800
-31.84
ROA % -15.99
CDXC's ROA % is ranked higher than
63% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CDXC: -15.99 )
Ranked among companies with meaningful ROA % only.
CDXC' s ROA % Range Over the Past 10 Years
Min: -3800  Med: -50.81 Max: -15.21
Current: -15.99
-3800
-15.21
ROC (Joel Greenblatt) % -31.42
CDXC's ROC (Joel Greenblatt) % is ranked higher than
69% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CDXC: -31.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CDXC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -381.66  Med: -157.99 Max: -31.42
Current: -31.42
-381.66
-31.42
3-Year Revenue Growth Rate 33.10
CDXC's 3-Year Revenue Growth Rate is ranked higher than
80% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CDXC: 33.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CDXC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.3 Max: 33.1
Current: 33.1
0
33.1
3-Year EBITDA Growth Rate -22.60
CDXC's 3-Year EBITDA Growth Rate is ranked lower than
75% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CDXC: -22.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CDXC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.5  Med: 6.8 Max: 143.4
Current: -22.6
-47.5
143.4
3-Year EPS without NRI Growth Rate -12.60
CDXC's 3-Year EPS without NRI Growth Rate is ranked lower than
63% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CDXC: -12.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CDXC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -41  Med: 0 Max: 146.6
Current: -12.6
-41
146.6
GuruFocus has detected 4 Warning Signs with ChromaDex Corp $CDXC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CDXC's 10-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:CDXC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2833
Compare:NAS:LPTX, OTCPK:PMCB, NAS:SNSS, NAS:RGLS, NAS:CASI, AMEX:ATNM, OTCPK:ARTH, NAS:SBPH, NAS:CXRX, NAS:LIFE, OTCPK:HPPI, NAS:ORMP, OTCPK:HBPCF, NAS:VCEL, NAS:AXSM, OTCPK:CYDY, NAS:SRRA, NAS:NEPT, AMEX:NAVB, OTCPK:CNNRF » details
Traded in other countries:OCD1.Germany,
Headquarter Location:USA
ChromaDex Corp is a natural products company that discovers, acquires, develops and commercializes patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.

ChromaDex Corp was formed as a California corporation on February 19, 2000. The Company, along with its subsidiaries supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of potential attributes, and reference materials, related contract services, technical consulting and proprietary ingredients. Through its subsidiaries, the Company provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks. The products and services includes dietary supplement and food ingredients, supply of reference standards, materials & kits, supply of fine chemicals and phytochemicals, contract services, consulting services and process development. The Company uses international distributors to market and sell to several foreign countries or markets. Its sales model for products and services is based on direct, inside technical sales. Its operations are subject to regulation by various United States federal agencies and similar state and international agencies, including the FDA, the Federal Trade Commission, the Department of Commerce, the Department of Transportation, the Department of Agriculture and other state and international agencies.

Top Ranked Articles about ChromaDex Corp

ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing
ChromaDex to Showcase Novel Ingredient Science and Brand-Elevating Services at Ingredient Marketplace 2017
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors

IRVINE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that Steven D. Rubin, J.D. has joined the Company’s board of directors. Mr. Rubin, age 56, has served as OPKO Health, Inc.’s (NASDAQ:OPK) Executive Vice President – Administration since May 2007 and as a director of since February 2007. Mr. Rubin is a member of The Frost Group, LLC, a private investment firm. He has extensive experience as a practicing lawyer, and as general counsel and board member to multiple public companies. Mr. Rubin currently serves on the board of directors for the following companies: VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing a next generation of vaccines; Cognit, Inc., a data and analytics company providing cloud-based mission-critical information and performance marketing solutions; Kidville, Inc., an operator of large, upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to five-year-olds; Non-Invasive Monitoring Systems, Inc., a medical device company; BioCardia, Inc., a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases; Cocrystal Pharma, Inc., a biotechnology company developing new treatments for viral diseases; Sevion Therapeutics, Inc., a clinical stage company which discovers and develops next-generation biologics for the treatment of cancer and immunological diseases; Castle Brands, Inc., a developer and marketer of premium brand spirits; and, Neovasc, Inc., a company developing and marketing medical specialty vascular devices. Mr. Rubin previously served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Mr. Rubin previously served as a director of the following companies: Dreams, Inc. ( MKT:DRJ), a vertically integrated sports licensing and products company; Safestitch Medical, Inc. prior to its merger with TransEnterix, Inc.; and, PROLOR Biotech, Inc., prior to its acquisition by the Company in August 2013. About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com. Forward-Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the composition and experience of ChromaDex’s board of directors. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
[email protected]

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
[email protected]

Read more...
ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017

Company Will Host Investor Conference Call on Friday, March 17, 2017

IRVINE, Calif., March 10, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it plans on reporting its year end 2016 financial results on Thursday, March 16, after the close of the financial markets.
ChromaDex management will host an investor conference call to discuss the year end results and provide a general business update on Friday, March 17, at 1 p.m. ET. Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows: U.S. Toll-Free Number:   (866) 327-8118 International Dial-In Number: (678) 509-7526 Conference ID:  86597553 Webcast link:  http://edge.media-server.com/m/p/y5kgkhmd/lan/en The webcast replay will be available after the completion of the call on the Investor Relations section of the Company website, www.chromadex.com.
The earnings press release, and its accompanying financial exhibits, will be available on the Investor Relations section of the Company website, www.chromadex.com. About ChromaDex:
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting. As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com. Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
[email protected]

ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
[email protected]

Read more...

Ratios

vs
industry
vs
history
Forward PE Ratio 15.63
CDXC's Forward PE Ratio is ranked higher than
52% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. CDXC: 15.63 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 11.13
CDXC's PB Ratio is ranked lower than
86% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CDXC: 11.13 )
Ranked among companies with meaningful PB Ratio only.
CDXC' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 17.68 Max: 69.44
Current: 11.13
2.46
69.44
PS Ratio 4.12
CDXC's PS Ratio is ranked higher than
77% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CDXC: 4.12 )
Ranked among companies with meaningful PS Ratio only.
CDXC' s PS Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.51 Max: 103.45
Current: 4.12
1.13
103.45
EV-to-EBIT -50.60
CDXC's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CDXC: -50.60 )
Ranked among companies with meaningful EV-to-EBIT only.
CDXC' s EV-to-EBIT Range Over the Past 10 Years
Min: -383.7  Med: -25.1 Max: -2.2
Current: -50.6
-383.7
-2.2
EV-to-EBITDA -60.53
CDXC's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CDXC: -60.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
CDXC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1187.8  Med: -27.9 Max: -2.6
Current: -60.53
-1187.8
-2.6
Current Ratio 1.77
CDXC's Current Ratio is ranked lower than
78% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CDXC: 1.77 )
Ranked among companies with meaningful Current Ratio only.
CDXC' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.73 Max: 4.3
Current: 1.77
0.92
4.3
Quick Ratio 0.88
CDXC's Quick Ratio is ranked lower than
86% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CDXC: 0.88 )
Ranked among companies with meaningful Quick Ratio only.
CDXC' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 0.87 Max: 3.05
Current: 0.88
0.5
3.05
Days Inventory 164.80
CDXC's Days Inventory is ranked lower than
61% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CDXC: 164.80 )
Ranked among companies with meaningful Days Inventory only.
CDXC' s Days Inventory Range Over the Past 10 Years
Min: 39.68  Med: 140.05 Max: 197.17
Current: 164.8
39.68
197.17
Days Sales Outstanding 79.67
CDXC's Days Sales Outstanding is ranked lower than
61% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CDXC: 79.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.27  Med: 40.64 Max: 79.67
Current: 79.67
28.27
79.67
Days Payable 146.54
CDXC's Days Payable is ranked higher than
76% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CDXC: 146.54 )
Ranked among companies with meaningful Days Payable only.
CDXC' s Days Payable Range Over the Past 10 Years
Min: 40.67  Med: 126.15 Max: 167.87
Current: 146.54
40.67
167.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
CDXC's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CDXC: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CDXC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -55.3  Med: -20.2 Max: -2.5
Current: -2.5
-55.3
-2.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 18.50
CDXC's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CDXC: 18.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CDXC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 14.25  Med: 33 Max: 65.14
Current: 18.5
14.25
65.14
Price-to-Tangible-Book 11.84
CDXC's Price-to-Tangible-Book is ranked lower than
80% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CDXC: 11.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CDXC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 9.01  Med: 17.59 Max: 29.04
Current: 11.84
9.01
29.04
Price-to-Median-PS-Value 0.63
CDXC's Price-to-Median-PS-Value is ranked higher than
76% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CDXC: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CDXC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 0.91 Max: 2.28
Current: 0.63
0.34
2.28
Earnings Yield (Greenblatt) % -1.97
CDXC's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CDXC: -1.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CDXC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.03  Med: 0 Max: 441.48
Current: -1.97
-3.03
441.48

More Statistics

Revenue (TTM) (Mil) $26.81
EPS (TTM) $ -0.08
Beta1.22
Short Percentage of Float4.81%
52-Week Range $2.25 - 6.18
Shares Outstanding (Mil)37.91

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 45 85 87
EPS ($) 0.16 0.36 0.35
EPS without NRI ($) 0.16 0.36 0.35
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:CDXC

Headlines

Articles On GuruFocus.com
ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing Apr 27 2017 
ChromaDex to Showcase Novel Ingredient Science and Brand-Elevating Services at Ingredient Marketplac Apr 11 2017 
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors Mar 28 2017 
ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017 Mar 10 2017 

More From Other Websites
ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing Apr 27 2017
ETFs with exposure to Chromadex Corp. : April 24, 2017 Apr 24 2017
ChromaDex to Showcase Novel Ingredient Science and Brand-Elevating Services at Ingredient... Apr 11 2017
ETFs with exposure to Chromadex Corp. : March 30, 2017 Mar 29 2017
ChromaDex to Present at the Cowen and Company’s 3rd Annual Future of the Consumer Conference:... Mar 29 2017
ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors Mar 28 2017
Chromadex Corp. :CDXC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 22, 2017 Mar 22 2017
Edited Transcript of CDXC earnings conference call or presentation 17-Mar-17 5:00pm GMT Mar 20 2017
ChromaDex Reports 2016 Record Revenue as Ingredient Sales Grew 34% Mar 16 2017
ChromaDex to Report Year End 2016 Financial Results on Thursday, March 16, 2017 Mar 10 2017
A Letter from the ChromaDex Chief Executive Officer Feb 23 2017
Study Published in PAIN Reveals Nicotinamide Riboside is an Effective Tool in Relieving... Feb 22 2017
ChromaDex to Showcase Premier Innovation and Brand-Elevating Science at Engredea 2017 Feb 21 2017
ChromaDex Expects to Report Record Fourth Quarter as Revenue Increased Approximately 29% Feb 14 2017
ETFs with exposure to Chromadex Corp. : January 24, 2017 Jan 24 2017
ETFs with exposure to Chromadex Corp. : December 13, 2016 Dec 13 2016
ETFs with exposure to Chromadex Corp. : November 30, 2016 Nov 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)